Conceptualization of CV events in the at-risk patient with B-cell malignancy. Absent BTKis, CV events would occur spontaneously at a given time point but ibrutinib (IBR), acalabrutinib (ACA), and zanubrutinib (ZAN) act as triggers that precipitate CV events at earlier time points, with the potency of triggering being IBR > ACA > ZAN.